Arcline Investment Management has acquired Polypeptide Therapeutic Solutions (PTS), a Spanish manufacturer of polyaminoacid-based drug delivery systems, from Columbus Venture Partners.

The financial terms of the deal were not disclosed by the parties.

Polypeptide Therapeutic Solutions is engaged in manufacturing polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications, which include mRNA, DNA, gene therapies, cell therapies, vaccines, biologics, and small molecule therapies.

Arcline Investment Management stated: “We believe that the success of nanoparticle delivery technologies in COVID-19 mRNA vaccines has permanently accelerated the funding, development, and adoption of these advanced drug delivery systems.

“PTS’ technology seeks to improve the efficiency, targeting, and safety profile of delivery systems for novel therapeutics, bringing urgently needed treatments to patients across multiple disease areas. We are excited to invest in PTS’ continued growth through the expansion of its GMP production and its technology portfolio.”

The service offerings of Polypeptide Therapeutic Solutions are preclinical development, GMP manufacturing, technology transfer, and fill & finish services.

Jose Vicente Pons Andreu – CEO of Polypeptide Therapeutic Solutions said: “Arcline is the right partner for us at a critical time when we must invest to meet our customers’ needs for scale in GMP production. They quickly saw the potential for our PAA technology platform to enable safer and more precise drug delivery.

“We look forward to working with them to expand our manufacturing footprint, accelerate our business development efforts, and bring new technologies to commercial scale.”

  Arcline Investment Management, Columbus Venture Partners, Jose Vicente Pons Andreu, Polypeptide Therapeutic Solutions, Spain